MPR for Stroke Risk Assessment of ICAS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorXuanwu Hospital, Beijing
About this trial
Intracranial atherosclerotic stenosis (ICAS) carries substantial stroke risk despite optimal medical treatment. Current risk stratification relies primarily on stenosis severity, but novel hemodynamic markers may improve prediction. In this multiple prospective registry study we aim to investigate whether regional hemodynamics, measured by a novel Magnetic resonance imaging-derived Pressure Ratio (MPR) technique, are associated with stroke risk in ICAS.
Eligibility criteria
Qualifiers
Adults aged 18 to 80 years.
Intracranial atherosclerotic stenosis ICAS involving a culprit artery in the anterior circulation.
Intracranial arterial stenosis of 50% to 99% as measured by the WASID method using TCD, CTA, MRA, or DSA.
Written informed consent obtained from the participant or a legal representative.
Disqualifiers
Non-atherosclerotic intracranial lesions, including moyamoya disease, vasculitis, vascular dissection, autoimmune diseases, or congenital/genetic abnormalities.
More than 50% stenosis of the extracranial carotid artery on the ipsilateral side.
Large cerebral infarction involving more than one-half of the territory on DWI imaging, or a baseline modified Rankin Scale score ≥3.
Contraindications to antiplatelet therapy or statins.
Trial design
Treatments tested in this trial
- Standardized medical therapy targeting vascular risk factors and stroke prevention
Treatment groups
400 Participants
are divided into 1 treatment groupSponsors and collaborators
Xuanwu Hospital, Beijing
Lead sponsor
Xuanwu Hebei Hospital
Collaborator
Xuanwu Xiongan Hospital
Collaborator
Xuanwu Chifeng Hospital
Collaborator
Xuanwu Jinan Hospital
Collaborator
Source ClinicalTrials.gov